Navigation Links
Kremers Urban Pharmaceuticals Inc. Announces Lipitor® Settlement Agreement

PRINCETON, N.J., Nov. 18, 2011 /PRNewswire/ -- Kremers Urban Pharmaceuticals Inc. today announced that it has entered into a settlement agreement which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets.  

The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

About Kremers Urban

Kremers Urban Pharmaceuticals Inc., a specialty generic drug manufacturer and subsidiary of Belgium-based UCB, is a pioneer in developing generic versions of pharmaceutical products that have a "high barrier to entry." The Company is moving to the forefront of delivering the tough solutions necessary to get complex products into the market. To learn more visit

For More Information Contact:

France Nivelle, Global Communications
+32 2 559 9178;

Antje Witte, Investor Relations
+32 2 559 9414;

SOURCE Kremers Urban Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Kremers Urban Pharmaceuticals Inc. Settles Concerta® Patent Litigation
2. Study Sheds Light on Young Suburban Heroin Users
3. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
4. CVS Caremark Showcases Workplace and Marketplace Diversity at 2011 National Urban League Conference
5. Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center
6. NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner
7. Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools
8. American Heart Association Rapid Access Journal Report: Implanted Monitor Accurately Detects Heart Rhythm Disturbances
9. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
10. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
11. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):